DH
Therapeutic Areas
NovoBiotic Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Teixobactin | Gram-positive bacterial infections (e.g., MRSA, VRE) and Nontuberculous Mycobacterial (NTM) lung infections | Preclinical |
| Clovibactin | Gram-positive bacterial infections (e.g., Staphylococcus aureus, Streptococcus pneumoniae) | Preclinical |
Leadership Team at NovoBiotic Pharmaceuticals
LL
Lucy Ling
VP of Biology
AS
Amy Spoering
Director of Biological Research
AP
Aaron Peoples
Director of Chemistry